Wilson disease is caused by mutations in the ATP7B gene, a gene whose definitive role is established by ClinGen. The ATP7B gene encodes a copper transporting enzyme that is essential for proper copper metabolism in the body. Disruption in the function of this protein leads to abnormal copper accumulation in multiple organs, including the liver and brain. The disease follows an autosomal recessive inheritance pattern, meaning that an affected individual typically inherits one mutated gene from each parent. This genetic basis provides a clear explanation for the multisystem symptoms observed in individuals diagnosed with the condition.

Diagnosing Wilson disease involves a comprehensive evaluation that integrates clinical findings, biochemical tests, and, when available, molecular genetic testing. The diagnostic approach is supported by well‐established clinical guidelines, including elements from the GeneReviews diagnostic algorithm. Though specific diagnostic methods are not detailed in this packet, the overall process often involves assessing copper metabolism markers alongside clinical evaluation. The diagnostic pathway typically combines evidence from liver function tests and neurological assessment, contributing to the overall clinical picture. These integrated approaches help in confirming the condition based on a combination of clinical and laboratory evidence.

Management of Wilson disease includes therapies that target the reduction of copper accumulation in affected individuals. Notably, FDA-approved treatments in this context include TRIENTINE TETRAHYDROCHLORIDE, marketed as CUVRIOR, and ZINC ACETATE, marketed as GALZIN. These approved therapeutic options have undergone regulatory review for their use in treating the condition. In addition to these agents, several other compounds hold orphan-designated status; however, these are not to be considered as current treatment options. The therapeutic approach, as outlined in the packet, emphasizes the importance of using approved treatments to manage copper levels and mitigate multisystem manifestations.

The outlook for individuals with Wilson disease can vary, as the clinical course depends on the extent of multisystem involvement and the timeliness of treatment initiation. According to expert reviews, untreated symptomatic patients may experience a variety of hepatic, neurological, psychiatric, or hematologic symptoms over a wide age range. Although the packet does not provide detailed natural history data, published clinical descriptions indicate that early recognition and treatment are essential in managing disease progression. Overall, the prognosis remains uncertain without treatment, and outcomes are influenced by the severity of copper accumulation and organ damage observed at diagnosis.

Numerous certified active trial records are present for Wilson disease, with over 30 active studies noted in the clinical trials database. Research efforts are focused on refining therapeutic strategies, including improved copper chelation and exploring novel treatment modalities. These studies seek to enhance understanding of the disease’s progression and to evaluate both traditional and innovative interventions. Active clinical trials for this condition are listed on ClinicalTrials.gov, and ongoing research continues to investigate mechanisms underlying copper dysregulation. This vibrant research landscape underscores the importance of continued investigation to improve patient outcomes over time.